cystic
fibrosi
cf
common
autosom
recess
genet
diseas
affect
multipl
organ
system
dr
dorothi
andersen
first
describ
diseas
cystic
fibrosi
pancrea
correl
malnutrit
sinc
discoveri
aggress
earli
intervent
establish
improv
qualiti
life
peopl
cf
howev
progress
lung
diseas
remain
difficult
manag
lead
caus
morbid
mortal
therapeut
small
molecul
provid
benefit
grow
percentag
peopl
cf
although
astound
progress
cystic
fibrosi
transmembran
conduct
regul
cftr
modul
expens
requir
lifetim
treatment
onetim
treatment
administ
earli
life
peopl
cf
might
prevent
onset
lung
diseas
figur
outlin
six
class
cftr
mutat
exampl
mutat
preval
within
us
popul
peopl
cf
small
molecul
therapeut
class
also
label
individu
may
differ
mutat
allel
individu
mutat
may
fit
one
categori
furthermor
new
mutat
subclass
propos
base
potenti
correct
therapi
potenti
small
molecul
treatment
continu
improv
expand
among
differ
mutat
perhap
addit
class
subclass
ad
although
develop
potenti
corrector
small
molecul
treatment
provid
relief
mani
peopl
cf
remain
unmet
need
mutat
benefit
treatment
thu
gene
therapi
mutat
agnost
approach
potenti
repair
phenotyp
defect
peopl
cf
cf
gene
therapi
clinic
trial
pioneer
logist
endpoint
assay
cf
well
pulmonari
diseas
exampl
nasal
potenti
differ
npd
forc
expiratori
volum
use
clinic
outcom
measur
cf
trial
quantifi
improv
lung
function
previous
review
improv
qualiti
life
follow
small
molecul
treatment
shed
light
diseas
target
inflamm
lesson
learn
treatment
sure
impact
futur
gene
therapi
clinic
trial
design
review
focu
histori
cf
gene
therapi
begin
discoveri
cftr
gene
continu
major
mileston
impact
field
look
futur
cf
gene
therapi
figur
gene
respons
cf
identifi
cftr
sequenc
identifi
multipl
cftr
mutat
commonli
threebas
delet
result
loss
phenylalanin
posit
clone
cftr
major
leap
studi
cf
quickli
launch
concept
genebas
therapeut
within
year
discov
cftr
two
group
independ
demonstr
proofofconcept
gene
therapi
express
full
length
cftr
complementari
dna
cdna
cf
cell
restor
anion
channel
activ
restor
cftr
activ
propos
cure
cf
soon
sever
studi
use
viral
nonvir
approach
deliv
cftr
correct
cf
defect
advanc
includ
adenoassoci
viru
aav
base
vector
adenoviru
ad
base
vector
plasmid
formul
cation
liposom
retrovir
vector
time
complement
cftr
cf
patient
consid
achiev
nearterm
goal
ensur
cftr
complement
restor
current
cf
cell
import
next
question
determin
percentag
correct
cell
necessari
therapeut
benefici
johnson
et
al
perform
first
studi
mix
cf
mlvcftr
transduc
cf
cell
vari
ratio
vitro
found
airway
cell
express
cftr
achiev
noncf
level
transport
studi
confirm
cftr
gene
deliveri
potenti
cur
strategi
establish
common
benchmark
success
gene
therapi
ie
transduct
airway
cell
rel
good
agreement
later
studi
suggest
express
cftr
cell
restor
wildtyp
level
whether
benchmark
truli
translat
clinic
efficaci
open
complex
question
howev
discuss
import
question
may
address
improv
gene
deliveri
tool
anim
model
also
time
function
cftr
assay
new
model
system
rapidli
develop
experi
perform
patientderiv
immort
cell
cf
pancreat
cell
human
bronchial
epitheli
cell
cf
bronchial
epitheli
cell
cell
establish
metric
quantifi
cftr
express
level
activ
includ
messeng
rna
mrna
abund
ratio
cftr
protein
band
c
band
b
measur
western
blot
situ
hybrid
iodid
efflux
patch
clamp
bioelectr
properti
measur
uss
chamber
prior
cf
anim
model
exist
test
function
gene
transfer
efficaci
vivo
howev
within
short
period
time
three
group
independ
gener
cf
mice
target
knockout
endogen
cftr
mice
exhibit
increas
steadyst
npd
compar
noncf
mice
alter
transport
abnorm
mucu
accumul
diseaserel
chang
lung
reproduct
tract
mice
develop
classic
cf
lung
diseas
similar
human
intestin
obstruct
also
report
consist
vitro
experi
cf
mous
model
transduct
cell
cftr
express
vector
yield
noncf
secret
time
studi
conduct
adbas
vector
wide
avail
product
method
establish
multipl
vivo
experi
examin
adbas
lung
gene
transfer
variou
model
repeat
dose
adlacz
cotton
rat
nonhuman
primat
show
ad
transduc
cell
within
proxim
bronchi
bronchiol
includ
ciliat
secretori
undifferenti
basal
cell
even
submucos
gland
safeti
repeat
ad
administr
evalu
studi
conclud
ad
deliveri
safe
exhibit
littl
immun
respons
upon
repeat
administr
studi
suggest
ad
promis
vector
cf
gene
therapi
zabner
et
al
first
publish
result
earli
cf
gene
therapi
clinic
trial
three
cf
patient
receiv
ad
vector
serotyp
carri
cftr
vector
appli
nasal
turbin
applic
min
remov
suction
one
three
day
later
one
side
biopsi
contralater
side
use
measur
npd
author
report
restor
npd
respons
camp
agonist
nasal
epithelia
howev
cftr
mrna
protein
undetect
retrospect
airway
injuri
deliveri
method
may
facilit
viral
transduct
parallel
zabner
studi
three
addit
adbas
clinic
trial
ensu
effort
restor
cftr
function
cf
patient
crystal
et
al
perform
phase
doseescal
studi
peopl
cf
conclud
pfu
led
cftr
dna
express
airway
epithelium
one
subject
receiv
pfu
right
lower
lobe
experienc
transient
system
inflamm
first
h
symptom
quickli
resolv
follow
show
longterm
effect
npd
result
studi
report
inconclus
ad
deliveri
nose
lung
appear
safe
knowl
et
al
use
ad
serotyp
vector
larger
studi
cf
particip
admedi
deliveri
cftr
correct
function
defect
perhap
due
inflammatori
respons
hay
et
al
deliv
nasal
epithelia
report
npd
decreas
toward
normal
compar
contralater
untreat
nostril
gener
studi
suggest
adbas
vector
could
partial
correct
transport
defect
cf
airway
epithelia
howev
effect
transient
inflammatori
respons
observ
although
sever
studi
show
partial
cftr
correct
cell
anim
model
use
ad
vector
result
clinic
trial
rais
question
safeti
efficaci
human
innat
cellular
immun
respons
present
obstacl
achiev
longterm
effici
gene
transfer
adbas
vector
nonhuman
primat
studi
report
increas
alveolar
inflamm
high
dose
ad
vector
although
ad
effici
deliv
gene
lung
transient
express
meant
repeat
administr
would
requir
studi
time
elucid
one
mechan
transgen
elimin
mediat
mhcii
present
viral
antigen
led
activ
cell
mice
immun
respons
also
induc
neutral
antibodi
format
serotypespecif
neutral
antibodi
ad
viral
capsid
antigen
found
prevent
readministr
ad
serotyp
effort
facilit
repeat
administr
includ
block
iga
antibodi
block
neutral
antibodi
nondeplet
antibodi
none
substanti
improv
repeat
ad
administr
determin
advector
readministr
could
achiev
longterm
cftr
express
peopl
cf
clinic
trial
test
safeti
effect
repeat
ad
administr
trial
featur
doseescal
repeat
dose
pfu
nasal
epithelium
cf
subject
conclud
vector
partial
correct
transport
defect
observ
signific
variabl
subject
note
found
less
cftrcorrect
administr
like
due
immun
respons
anoth
clinic
trial
bellon
et
al
report
toxic
effect
use
dose
pfu
detect
cftr
dna
mrna
clinic
trial
occur
time
use
addit
delet
report
transient
express
second
administr
low
effici
lower
respiratori
tract
short
durat
express
overal
repeat
dose
ad
effect
therapeut
option
clinic
trial
ornithin
transcarbamylas
otc
defici
vector
carri
otc
gene
deliv
male
subject
name
jess
gelsing
receiv
dose
viral
particl
via
femor
arteri
deliveri
liver
four
day
administr
die
multipl
organ
failur
associ
cytokin
storm
although
diseas
unrel
cf
tragic
demonstr
high
system
dose
ad
fatal
total
cf
clinic
trial
use
ad
deliveri
vehicl
last
publish
first
decad
cf
gene
therapi
concept
cftr
complement
firmli
establish
howev
scientist
clinician
learn
deliveri
function
cftr
airway
human
challeng
origin
anticip
cf
clinic
trial
use
adbas
vector
gener
support
gene
therapi
potenti
therapeut
benefit
improv
vector
design
deliveri
effici
necessari
correct
cf
lung
diseas
figur
similar
ad
recombin
aav
vector
transduc
termin
differenti
nondivid
cell
aav
persist
episom
integr
absenc
exogen
rep
protein
preclin
studi
cftr
express
aav
serotyp
vector
persist
rhesu
macaqu
month
singl
deliveri
lung
shown
safe
newborn
rabbit
aav
transduc
alveolar
epitheli
cell
tracheobronchi
ciliat
lung
cell
vector
dna
detect
month
function
cftr
activ
demonstr
cultur
cell
iodid
efflux
assay
although
earli
persist
result
encourag
aav
express
decreas
time
loss
express
attribut
dilut
transduc
cell
lung
growth
lack
stem
cell
transduct
aav
could
readminist
persist
month
follow
transient
immunosuppress
ligand
antibodi
solubl
fusion
protein
thu
singl
dose
aav
transduc
airway
confer
stabl
express
mani
month
time
period
aav
vector
forefront
cf
gene
therapi
mani
studi
show
safeti
efficaci
repeat
dose
nonhuman
primat
mice
even
presenc
neutral
antibodi
serotyp
studi
cell
cultur
ferret
pig
show
transduct
pattern
close
mirror
human
airway
epithelia
mice
reflect
trend
studi
mice
evalu
variou
promot
ultim
led
gener
hybrid
promot
includ
splice
donor
splice
acceptor
term
cag
promot
promot
substanti
increas
transgen
express
airway
epithelia
vitro
deliv
cftr
aav
help
uncov
featur
cftr
biolog
exampl
aavmedi
cftr
deliveri
mous
airway
expos
correl
gene
transfer
mrna
level
suggest
regulatori
role
low
level
cftr
mrna
activ
chlorid
channel
multipl
vitro
vivo
studi
suggest
aav
could
effici
restor
cftr
express
airway
epitheli
cell
first
aav
serotyp
vector
clinic
trial
test
singl
two
dose
treatment
report
safe
dosedepend
gene
transfer
maxillari
sinu
littl
cytopath
host
immun
respons
midst
design
test
new
vector
three
addit
singl
dose
aav
clinic
trial
took
place
result
dose
escal
aav
clinic
trial
cf
publish
trial
use
aav
carri
full
length
cftr
cdna
driven
promot
activ
aav
itr
total
aav
clinic
trial
fail
meet
trial
endpoint
detect
cftr
dna
nasal
brush
pcr
chang
npd
chang
specifi
metric
measur
high
resolut
ct
scan
improv
gener
aav
deliveri
consid
safe
howev
result
level
cftr
express
typic
limit
detect
despit
low
cftr
express
level
result
encourag
demonstr
safeti
vector
limit
aav
cf
gene
therapi
small
carri
capac
kb
aav
invert
termin
repeat
itr
shown
possess
promot
activ
mediat
stabl
low
level
cftr
express
vitro
addit
intern
promot
polyadenyl
signal
necessari
exceed
carri
capac
delet
analysi
show
remov
portion
rdomain
shorten
cftr
nearli
base
pair
still
retain
anion
channel
function
similar
extent
wildtyp
cftr
address
aav
packag
constraint
addit
studi
shorten
express
cassett
compon
led
gener
shorten
cmvie
cytomegaloviru
immedi
earli
promot
polya
aav
vector
modif
deliv
function
cftr
correct
anion
channel
defect
vitro
cftr
minigen
complement
intestin
defect
cftr
null
mice
altern
viral
vector
new
focu
direct
toward
nonvir
strategi
cftr
deliveri
nonvir
vector
deliveri
entic
approach
size
constraint
howev
effici
deliveri
cell
challeng
challeng
commonli
address
formul
plasmid
dna
cation
lipid
import
mechanist
studi
time
show
plasmid
complex
lipid
traffic
vesicl
unpack
prior
reach
nucleu
mani
cation
lipid
test
report
safe
plasmid
deliveri
vehicl
gene
transfer
first
nonvir
clinic
trial
caplen
et
al
cation
lipid
complex
cftr
show
partial
npd
correct
campmedi
transport
nasal
epithelium
six
peopl
cf
approxim
noncf
level
hyde
et
al
perform
repeat
administr
trial
nonvir
complex
deliv
nose
report
loss
efficaci
repeat
administr
seven
subsequ
nonvir
clinic
trial
report
partial
transient
express
last
longer
week
wave
nonvir
clinic
trial
lull
activ
nearli
decad
focu
improv
deliveri
gene
express
perhap
ambiti
nonvir
clinic
trial
date
alton
colleagu
nebul
cftr
plasmid
formul
cation
lipid
lung
peopl
cf
report
increas
howev
despit
encourag
result
nonvir
approach
deliv
cftr
enough
achiev
clear
phenotyp
correct
late
viral
vector
deliveri
method
steadili
improv
detail
vectorhost
interact
elucid
exampl
mulvbas
vector
integr
divid
cell
keratinocyt
growth
factor
kgf
found
stimul
prolifer
airway
epitheli
cell
improv
mulv
gene
transfer
efficaci
addit
ethylen
glycolbi
ether
n
n
acid
egta
treatment
formul
enhanc
transepitheli
permeabl
gene
transfer
vsvg
pseudotyp
mulv
studi
use
retrovir
vector
report
enhanc
gene
transfer
mice
injuri
sulfur
dioxid
retroviru
studi
rabbit
tracheal
epitheli
cell
also
report
persist
express
follow
transduct
airway
epitheli
cell
howev
transduct
occur
wound
trachea
first
studi
shed
light
receptor
access
cell
polar
influenc
transduct
effici
lentivir
vector
welcom
promis
therapeut
option
genom
integr
could
provid
longterm
express
primat
nonprim
lentivir
vector
quickli
replac
retrovir
vector
could
effect
transduc
nondivid
airway
cell
specif
felin
immunodefici
viru
fiv
vector
transduc
nondivid
airway
epitheli
cell
persist
express
transgen
interest
correct
cftr
defect
vitro
modif
lentivir
vector
also
improv
gene
transfer
although
typic
pseudotyp
vesicular
stomat
viru
vsvg
basolater
entri
prefer
hinder
effici
airway
gene
transfer
envelop
glycoprotein
respiratori
syncyti
viru
rsv
marburg
ebola
viru
influenza
sever
acut
respiratori
syndrom
sar
spike
protein
jaagsiekt
sheep
retroviru
jsrv
baculoviru
sendai
fhn
evalu
apic
entri
properti
led
studi
lentivirus
becam
new
interest
field
cf
gene
therapi
mani
studi
confirm
primat
nonprim
lentivir
vector
promis
gene
therapi
candid
vsvgpseudotyp
human
immunodefici
viru
hiv
cftr
lysophosphatidylcholin
lpc
pretreat
achiev
persist
cftr
express
least
month
cfnull
mice
addit
sendai
viru
fhn
protein
use
pseudotyp
simian
immunodefici
viru
siv
deriv
lentivir
vector
carri
cftr
correct
cf
defect
vitro
pseudotyp
fiv
shown
support
gene
transfer
pig
model
hivbas
lentivirus
also
transduc
marmoset
lung
achiev
longterm
correct
cf
mice
although
much
progress
made
understand
viral
nonvir
vector
deliveri
method
sever
barrier
remain
exampl
sinc
wildtyp
adenoviru
respiratori
viru
assum
enter
airway
epitheli
cell
apic
surfac
howev
transduct
ineffici
vivo
suggest
ad
prefer
basolater
entri
perhap
due
receptormedi
entri
support
find
egta
treatment
enhanc
ad
gene
transfer
mous
airway
disrupt
tight
junction
discoveri
coxsackieviru
adenoviru
receptor
car
confirm
receptor
inde
local
basolater
surfac
studi
redirect
car
apic
surfac
human
airway
epitheli
cell
use
glycosylphosphatidylinositol
gpi
linkag
increas
apic
gene
transfer
seri
event
exemplifi
use
vehicl
formul
overcom
physic
immunolog
barrier
vector
inde
mani
vehicl
formul
evalu
abil
improv
receptor
access
reduc
immunostimul
upon
entri
mean
increas
transduct
effici
viral
vector
formul
polyc
neutral
neg
charg
vector
surfac
glycoprotein
increas
transduct
transgen
express
exampl
includ
polybren
protamin
diethylaminoethyl
deae
dextran
polyllysin
cation
lipid
viscoelast
gel
formul
also
improv
apic
gene
transfer
one
vector
class
agent
natur
airway
surfact
lpc
calcium
chelat
egta
employ
transient
disrupt
epitheli
tight
junction
improv
vsvghiv
entri
vivo
precipit
ad
use
calcium
phosphat
enhanc
gene
transfer
receptorindepend
endocytosi
formul
ad
dexamethason
reduc
inflamm
use
polidocanol
disrupt
tight
junction
use
improv
apic
bind
method
enhanc
gene
transfer
mani
vehicl
experi
sinc
becom
wide
use
preclin
studi
play
major
role
enhanc
receptor
access
gene
transfer
addit
effort
improv
transgen
deliveri
understand
cftr
express
explor
vector
design
select
promot
polya
signal
appropri
strength
might
improv
cftr
express
increas
anion
channel
express
potenti
achiev
therapeut
level
correct
cell
transduc
pgk
cmv
promot
compar
context
bovin
growth
hormon
bgh
poli
signal
novel
hybrid
cmv
enhanc
term
hcef
promot
develop
nonvir
clinic
trial
prove
efficaci
due
size
limit
aav
packag
capac
develop
minim
synthet
promot
also
facilit
improv
cftr
express
aav
vector
inclus
induc
promot
regul
transgen
express
level
modifi
cftr
express
cassett
novel
way
regul
gene
express
vector
design
select
transgen
express
epithelia
first
document
show
cytokeratin
promot
drive
cftr
express
airway
epitheli
cell
sever
advanc
vector
design
help
aav
gene
transfer
steadili
move
forward
codeliveri
aav
proteasom
inhibitor
doxorubicin
llnl
increas
express
airway
cell
prevent
proteasom
degrad
vector
direct
evolut
aav
capsid
human
airway
epitheli
cell
led
develop
capsid
improv
apic
transduct
properti
human
airway
epithelia
novel
aav
capsid
variant
deriv
gener
direct
evolut
improv
cftr
deliveri
dual
report
gene
studi
chimpanze
airway
shown
transduc
higher
day
postdeliveri
studi
use
aav
show
incorpor
peptid
motif
aav
capsid
improv
gene
transfer
human
airway
epitheli
cell
circumv
harm
immunostimulatori
properti
ad
helperdepend
ad
hdad
also
known
deltarad
gut
ad
develop
express
viral
protein
strategi
reduc
immun
respons
viral
antigen
effort
provid
safer
ad
vector
option
cf
gene
therapi
studi
compar
first
gener
ad
hdad
focus
understand
innat
immun
respons
exampl
system
level
elev
follow
multipl
rout
vector
instil
howev
use
hdad
led
reduc
level
inflamm
interestingli
decreas
lung
bacteri
infect
restor
cftr
airway
mice
hdad
readminist
mous
lung
reduc
innat
immun
respons
continu
improv
gene
transfer
vector
provid
expand
toolbox
deliveri
option
figur
complementari
approach
gene
addit
abil
enzymat
modifi
nucleic
acid
sequenc
advanc
new
field
studi
cf
research
commun
gene
edit
tool
includ
zfn
talen
meganucleas
zinc
finger
nucleas
earli
gene
edit
tool
howev
eas
engin
guid
rna
product
allow
broader
access
genom
modif
tool
gene
edit
hold
promis
repair
endogen
cftr
gene
restor
cftr
function
repair
individu
mutat
insert
partial
fulllength
cdna
safesit
target
integr
howev
vivo
gene
repair
face
obstacl
extend
beyond
associ
simpl
gene
deliveri
cftr
mutat
effici
introduc
doubl
strand
break
differ
guid
rna
effici
homolog
recombin
differ
repair
templat
need
assess
cftr
gene
edit
zfn
talen
method
evalu
vitro
importantli
gene
addit
gene
repair
strategi
reli
effici
vivo
gene
deliveri
interest
includ
deliveri
respiratori
epithelia
system
deliveri
strategi
might
correct
cf
defect
multipl
affect
organ
whether
goal
gene
addit
gene
repair
gene
therapi
success
vector
select
must
either
integr
basal
cell
progenitor
cell
type
readminist
aav
ad
hdad
gener
consid
nonintegr
develop
hybrid
nonvir
transposonvir
integr
vector
system
led
persist
express
mice
least
year
previous
dna
transposon
piggybac
shown
promot
persist
gene
transfer
mice
system
piggybacaav
piggybacad
vector
system
confer
persist
express
mous
airway
presenc
transposas
recent
studi
pig
model
document
whole
lung
distribut
piggybacad
vector
phenotyp
correct
cf
pig
model
promis
work
evalu
hdad
suggest
vector
effici
transduc
airway
epithelia
includ
submucos
gland
readminist
use
immunosuppress
perhap
integr
piggybachdad
could
provid
longterm
effici
correct
readminist
necessari
advanc
gene
therapi
genet
diseas
continu
inform
field
decemb
fda
approv
voretigen
neparvovecrzyl
luxturna
gene
therapi
treatment
individu
inherit
retin
diseas
retin
pigmentosa
leber
congenti
amaurosi
treatment
vector
carri
deliv
inject
subretin
space
individu
receiv
treatment
exhibit
increas
fullfield
light
sensit
improv
fmri
result
excit
advanc
cart
therapi
cancer
treatment
includ
tisagenlecleucel
kymriah
axicabtagen
ciloleucel
yescarta
chimer
antigen
receptor
deliv
lentivir
vector
autolog
cell
patient
achiev
complet
remiss
gene
therapi
approv
use
europ
includ
alofisel
spherox
zalmoxi
stimv
imlyg
holoclar
european
medicin
agenc
steadili
grow
list
clinic
approv
gene
therapi
therapeut
suggest
may
enter
new
era
gene
therapi
commonplac
option
current
excit
new
develop
cf
gene
therapi
nanoparticl
deliveri
chemistri
enhanc
tropism
emerg
cf
clinic
trial
use
lentivir
vector
current
pursu
major
breakthrough
gene
therapi
genet
diseas
fuel
new
interest
cf
field
gene
therapi
learn
valuabl
lesson
mani
viral
nonvir
clinic
trial
date
develop
new
vector
effici
persist
correct
cftr
anion
channel
defect
new
anim
model
recapitul
featur
human
lung
diseas
allow
preclin
studi
refin
deliveri
protocol
measur
novel
metric
phenotyp
correct
earli
surg
enthusiasm
develop
gene
therapi
treatment
cf
fell
realiz
deliv
cftr
lung
complex
expect
improv
vector
design
deliveri
method
understand
lung
biolog
diseas
develop
abil
use
new
anim
model
reenerg
gene
therapi
field
ad
momentum
hope
lead
gener
effect
therapeut
reagent
cf
